CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER

摘要: Compelling experimental and clinical evidence suggests that epidermal growth factor receptor (EGFR) plays an important role in pathogenesis of a variety human cancers, thus providing strong rationale for the development antagonists as effective specific therapeutic strategies treatment EGFR-expressing cancers. Cetuximab (Erbitux®, IMC-C225), chimeric monoclonal antibody directed against EGFR, is first only FDA-approved anti-EGFR patients with refractory metastatic colorectal cancer (mCRC). has demonstrated significant antitumor activity, both single agent combination irinotecan, mCRC to irinotecan therapy. Cetuximab, via blocking ligand/receptor interaction, exerts its biological activity multiple mechanisms, including inhibition cell-cycle progression, potentiation cell apoptosis, DNA repair, angiogenesis, tumor-cell invasion metastasis, potentially induction immunological effector mechanisms. currently being tested advanced trials various patients, those squamous carcinoma head neck, non–small lung cancer, pancreatic ovarian cancer.